Inicio
Información del autor
Autor Luis Vicente Syro Moreno
Comentario :
Médico Neurocirujano, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (77)
Refinar búsqueda
Título : Undifferentiated sarcoma of the sellar region Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Endocrine Pathology Idioma : Inglés (eng) Palabras clave : Undifferentiated sarcoma sella turcica rhabdomyosarcoma immunohistochemistry Resumen : Malignancies lacking specific features of cellular maturation are termed “undifferentiated” and represent 5–10% of all human tumors. They are encountered at a variety of sites but do not, as a rule, arise in the sellar region. A 39-year-old male with a history of testicular seminoma and an unsuccessful biopsy of a third ventricular neoplasm, presented with visual disturbances and memory loss. Light microscopically, the tumor consisted entirely of undifferentiated spindle cells. No germ cell component was noted. An exhaustive immunohistochemical study found immunoreactivity for vimentin and desmin, but for no other myoid markers. Polymerase chain reaction showed no X;18 translocation. Based upon these studies, a diagnosis of “undifferentiated sarcoma” was made. Our case, being highly unusual among reported sellar neoplasms, underscores the difficulties inherent in the differential diagnosis of undifferentiated neoplasms. Mención de responsabilidad : Branavan Manoranjan, Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Eva Horvath, Fateme Salehi, Kalman Kovacs, Michael D Cusimano Referencia : Endocr Pathol. 2011 Sep;22(3):159-64. DOI (Digital Object Identifier) : 10.1007/s12022-011-9166-7 PMID : 21681665 En línea : https://link.springer.com/article/10.1007%2Fs12022-011-9166-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3566 Undifferentiated sarcoma of the sellar region [documento electrónico] / Luis Vicente Syro Moreno, . - 2011.
Obra : Endocrine Pathology
Idioma : Inglés (eng)
Palabras clave : Undifferentiated sarcoma sella turcica rhabdomyosarcoma immunohistochemistry Resumen : Malignancies lacking specific features of cellular maturation are termed “undifferentiated” and represent 5–10% of all human tumors. They are encountered at a variety of sites but do not, as a rule, arise in the sellar region. A 39-year-old male with a history of testicular seminoma and an unsuccessful biopsy of a third ventricular neoplasm, presented with visual disturbances and memory loss. Light microscopically, the tumor consisted entirely of undifferentiated spindle cells. No germ cell component was noted. An exhaustive immunohistochemical study found immunoreactivity for vimentin and desmin, but for no other myoid markers. Polymerase chain reaction showed no X;18 translocation. Based upon these studies, a diagnosis of “undifferentiated sarcoma” was made. Our case, being highly unusual among reported sellar neoplasms, underscores the difficulties inherent in the differential diagnosis of undifferentiated neoplasms. Mención de responsabilidad : Branavan Manoranjan, Luis V Syro, Bernd W Scheithauer, Leon D Ortiz, Eva Horvath, Fateme Salehi, Kalman Kovacs, Michael D Cusimano Referencia : Endocr Pathol. 2011 Sep;22(3):159-64. DOI (Digital Object Identifier) : 10.1007/s12022-011-9166-7 PMID : 21681665 En línea : https://link.springer.com/article/10.1007%2Fs12022-011-9166-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3566 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000135 AC-2011-020 Archivo digital Producción Científica Artículos científicos Disponible Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes / Luis Vicente Syro Moreno
Título : Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2010 Títulos uniformes : Neoplasma Idioma : Inglés (eng) Palabras clave : immunohistochemistry endoglin CD34 microvascular density angiogenesis pituitary Resumen : Vascularization is a prerequisite of tumor growth, invasion and metastasis. In the present work, microvessel density was assessed by quantitating using two different endothelial cell biomarkers, endoglin (CD-105) and CD-34. Fifty endocrinologically active and 36 clinically nonfunctioning pituitary adenomas, all surgically resected, as well as 10 autopsy-derived normal adenohypophyses were investigated by immunohistochemistry. The results showed that in every pituitary adenoma type endoglin, an assumed biomarker of proliferating endothelial cells, immunostained fewer vessels than CD-34 which revealed immunopositivity in all capillaries. Differences in endoglin versus CD-34 immunoexpression indicate varying degrees of vascularity in pituitary adenoma subtypes. The low levels of endoglin immunoexpression in pituitary tumors exposed to long-acting somatostatin analogs and dopamine agonists are consistent with the view that these agents inhibit angiogenesis. Mención de responsabilidad : F Rotondo, S Sharma, B W Scheithauer, E Horvath, L V Syro, M Cusimano, F Nassiri, G M Yousef, K Kovacs Referencia : Neoplasma. 2010;57(6):590-3. DOI (Digital Object Identifier) : 10.4149/neo_2010_06_590 PMID : 20845998 En línea : http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&produ [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4470 Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes [documento electrónico] / Luis Vicente Syro Moreno, . - 2010.
Obra : Neoplasma
Idioma : Inglés (eng)
Palabras clave : immunohistochemistry endoglin CD34 microvascular density angiogenesis pituitary Resumen : Vascularization is a prerequisite of tumor growth, invasion and metastasis. In the present work, microvessel density was assessed by quantitating using two different endothelial cell biomarkers, endoglin (CD-105) and CD-34. Fifty endocrinologically active and 36 clinically nonfunctioning pituitary adenomas, all surgically resected, as well as 10 autopsy-derived normal adenohypophyses were investigated by immunohistochemistry. The results showed that in every pituitary adenoma type endoglin, an assumed biomarker of proliferating endothelial cells, immunostained fewer vessels than CD-34 which revealed immunopositivity in all capillaries. Differences in endoglin versus CD-34 immunoexpression indicate varying degrees of vascularity in pituitary adenoma subtypes. The low levels of endoglin immunoexpression in pituitary tumors exposed to long-acting somatostatin analogs and dopamine agonists are consistent with the view that these agents inhibit angiogenesis. Mención de responsabilidad : F Rotondo, S Sharma, B W Scheithauer, E Horvath, L V Syro, M Cusimano, F Nassiri, G M Yousef, K Kovacs Referencia : Neoplasma. 2010;57(6):590-3. DOI (Digital Object Identifier) : 10.4149/neo_2010_06_590 PMID : 20845998 En línea : http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&produ [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4470 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000970 AC-2010-060 Archivo digital Producción Científica Artículos científicos Disponible Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome / Luis Vicente Syro Moreno
Título : Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2010 Títulos uniformes : Endocrine Pathology Idioma : Inglés (eng) Resumen : MGMT expression in tumors has been correlated with response to treatment with temozolomide therapy. Few medical therapies are available for Nelson syndrome, and the efficacy of such therapeutics remains limited. The aim of the present study was to assess immunohistochemical expression of MGMT in ACTH-secreting pituitary adenomas of patients with Nelson syndrome. Our material consisted of eight specimens from ACTH-secreting pituitary adenomas of patients with Nelson syndrome. Immunohistochemical staining for MGMT was performed using the streptavidin-biotin-peroxidase complex method. MGMT immunoreactivity was assessed microscopically and recorded as an estimated percentage of nuclear MGMT immunostaining (0 = none, 1=50%). Five of the eight specimens (65%) exhibited no MGMT immunoreactivity, with two out of eight cases (25%) showing slight MGMT staining ( Mención de responsabilidad : Fateme Salehi, Bernd W Scheithauer, Veronica J Moyes, William M Drake, Luis V Syro, Branavan Manoranjan, Soniya Sharma, Eva Horvath, Kalman Kovacs Referencia : Endocr Pathol. 2010 Dec;21(4):227-9. DOI (Digital Object Identifier) : 10.1007/s12022-010-9138-3 PMID : 21061089 En línea : https://link.springer.com/article/10.1007/s12022-010-9138-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3507 Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome [documento electrónico] / Luis Vicente Syro Moreno, . - 2010.
Obra : Endocrine Pathology
Idioma : Inglés (eng)
Resumen : MGMT expression in tumors has been correlated with response to treatment with temozolomide therapy. Few medical therapies are available for Nelson syndrome, and the efficacy of such therapeutics remains limited. The aim of the present study was to assess immunohistochemical expression of MGMT in ACTH-secreting pituitary adenomas of patients with Nelson syndrome. Our material consisted of eight specimens from ACTH-secreting pituitary adenomas of patients with Nelson syndrome. Immunohistochemical staining for MGMT was performed using the streptavidin-biotin-peroxidase complex method. MGMT immunoreactivity was assessed microscopically and recorded as an estimated percentage of nuclear MGMT immunostaining (0 = none, 1=50%). Five of the eight specimens (65%) exhibited no MGMT immunoreactivity, with two out of eight cases (25%) showing slight MGMT staining ( Mención de responsabilidad : Fateme Salehi, Bernd W Scheithauer, Veronica J Moyes, William M Drake, Luis V Syro, Branavan Manoranjan, Soniya Sharma, Eva Horvath, Kalman Kovacs Referencia : Endocr Pathol. 2010 Dec;21(4):227-9. DOI (Digital Object Identifier) : 10.1007/s12022-010-9138-3 PMID : 21061089 En línea : https://link.springer.com/article/10.1007/s12022-010-9138-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3507 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000076 AC-2010-008 Archivo digital Producción Científica Artículos científicos Disponible
Título : MGMT immunoexpression in aggressive pituitary adenoma and carcinoma Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2010 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Pituitary carcinoma pituitary adenoma temozolomide MGMT treatment Resumen : Recent case reports have documented the efficacy of temozolomide therapy in some aggressive pituitary adenomas and pituitary carcinomas resistant to multimodality therapy. Evidence suggests that low O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression correlates with response to temozolomide chemotherapy. Herein, we aimed to study MGMT immunoexpression in a spectrum of pituitary tumors, indolent, aggressive and malignant. A literature review of the use of temozolomide in pituitary tumors was also performed. Immunohistochemistry for MGMT was performed on 60 pituitary tumors identified in the Mayo Clinic Tissue Registry and the consultation files of one of us (BWS). The group included 30 pituitary carcinomas (15 ACTH, 10 PRL, 1 FSH/LH, 1 TSH, 1 silent subtype 3 and 2 null cell). Tissue from recurrences was available in 17 cases. In addition, 30 functionally different pituitary adenomas were studied, including 15 invasive and 15 non-invasive adenomas. Overall, 32 cases of pituitary tumors (54%) demonstrated low MGMT immunoexpression. This included 17 of 30 (57%) carcinomas, 9 of 15 (60%) invasive adenomas, and 6 of 15 cases (40%) of non-invasive pituitary adenomas. There was no significant change in MGMT immunoexpression between primary and recurrent tumors. Prolactin-producing carcinomas had the highest proportion of tumors (80%) with low expression. A signifi- cant proportion of pituitary adenomas and carcinomas demonstrate low MGMT immunoexpression. In an effort to anticipate the likelihood of a temozolomide response, all cases of aggressive pituitary tumors should be assessed for MGMT expression. Mención de responsabilidad : Queenie Lau, Bernd Scheithauer, Kalman Kovacs, Eva Horvath, Luis V Syro, Ricardo Lloyd Referencia : Pituitary. 2010 Dec;13(4):367-79. DOI (Digital Object Identifier) : 10.1007/s11102-010-0249-0 PMID : 20740317 En línea : https://link.springer.com/article/10.1007%2Fs11102-010-0249-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3541 MGMT immunoexpression in aggressive pituitary adenoma and carcinoma [documento electrónico] / Luis Vicente Syro Moreno, . - 2010.
Obra : Pituitary
Idioma : Inglés (eng)
Palabras clave : Pituitary carcinoma pituitary adenoma temozolomide MGMT treatment Resumen : Recent case reports have documented the efficacy of temozolomide therapy in some aggressive pituitary adenomas and pituitary carcinomas resistant to multimodality therapy. Evidence suggests that low O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression correlates with response to temozolomide chemotherapy. Herein, we aimed to study MGMT immunoexpression in a spectrum of pituitary tumors, indolent, aggressive and malignant. A literature review of the use of temozolomide in pituitary tumors was also performed. Immunohistochemistry for MGMT was performed on 60 pituitary tumors identified in the Mayo Clinic Tissue Registry and the consultation files of one of us (BWS). The group included 30 pituitary carcinomas (15 ACTH, 10 PRL, 1 FSH/LH, 1 TSH, 1 silent subtype 3 and 2 null cell). Tissue from recurrences was available in 17 cases. In addition, 30 functionally different pituitary adenomas were studied, including 15 invasive and 15 non-invasive adenomas. Overall, 32 cases of pituitary tumors (54%) demonstrated low MGMT immunoexpression. This included 17 of 30 (57%) carcinomas, 9 of 15 (60%) invasive adenomas, and 6 of 15 cases (40%) of non-invasive pituitary adenomas. There was no significant change in MGMT immunoexpression between primary and recurrent tumors. Prolactin-producing carcinomas had the highest proportion of tumors (80%) with low expression. A signifi- cant proportion of pituitary adenomas and carcinomas demonstrate low MGMT immunoexpression. In an effort to anticipate the likelihood of a temozolomide response, all cases of aggressive pituitary tumors should be assessed for MGMT expression. Mención de responsabilidad : Queenie Lau, Bernd Scheithauer, Kalman Kovacs, Eva Horvath, Luis V Syro, Ricardo Lloyd Referencia : Pituitary. 2010 Dec;13(4):367-79. DOI (Digital Object Identifier) : 10.1007/s11102-010-0249-0 PMID : 20740317 En línea : https://link.springer.com/article/10.1007%2Fs11102-010-0249-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3541 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000111 AC-2010-043 Archivo digital Producción Científica Artículos científicos Disponible Collision tumors of the sella: Craniopharyngioma and silent pituitary adenoma subtype 3: Case report / Luis Vicente Syro Moreno ; Alejandro Daniel Velásquez Urzola
Título : Collision tumors of the sella: Craniopharyngioma and silent pituitary adenoma subtype 3: Case report Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, ; Alejandro Daniel Velásquez Urzola, Fecha de publicación : 2009 Títulos uniformes : Endocrine Pathology Idioma : Inglés (eng) Palabras clave : sella turcica collision tumors craniopharyngioma silent pituitary adenoma subtype 3 Resumen : Collision tumors of the sella turcica are rare and consist mainly of more than one type of pituitary adenoma, usually a corticotropin- and a prolactin-producing adenoma. The association of a craniopharyngioma and a pituitary adenoma is rare. Herein, we report the first case of an association between craniopharyngioma and silent pituitary adenoma subtype 3. It involved a 12-year-old boy who underwent a frontal craniotomy with surgical removal of a calcified sellar tumor. Histology revealed an adamantinomatous craniopharyngioma; however, by electron microscopy, there was conclusive evidence of adenoma cells showing the ultrastructural features of silent pituitary adenoma subtype 3. Endocrine and neuroimaging as well as detailed immunohistochemical and ultrastructural studies were undertaken. The literature is also reviewed. Mención de responsabilidad : Olga Moshkin, Bernd W Scheithauer, Luis V Syro, Alejandro Velasquez, Eva Horvath, Kalman Kovacs Referencia : Endocr Pathol. Spring 2009;20(1):50-5. DOI (Digital Object Identifier) : 10.1007/s12022-009-9065-3 PMID : 19238590 En línea : https://link.springer.com/article/10.1007/s12022-009-9065-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4456 Collision tumors of the sella: Craniopharyngioma and silent pituitary adenoma subtype 3: Case report [documento electrónico] / Luis Vicente Syro Moreno, ; Alejandro Daniel Velásquez Urzola, . - 2009.
Obra : Endocrine Pathology
Idioma : Inglés (eng)
Palabras clave : sella turcica collision tumors craniopharyngioma silent pituitary adenoma subtype 3 Resumen : Collision tumors of the sella turcica are rare and consist mainly of more than one type of pituitary adenoma, usually a corticotropin- and a prolactin-producing adenoma. The association of a craniopharyngioma and a pituitary adenoma is rare. Herein, we report the first case of an association between craniopharyngioma and silent pituitary adenoma subtype 3. It involved a 12-year-old boy who underwent a frontal craniotomy with surgical removal of a calcified sellar tumor. Histology revealed an adamantinomatous craniopharyngioma; however, by electron microscopy, there was conclusive evidence of adenoma cells showing the ultrastructural features of silent pituitary adenoma subtype 3. Endocrine and neuroimaging as well as detailed immunohistochemical and ultrastructural studies were undertaken. The literature is also reviewed. Mención de responsabilidad : Olga Moshkin, Bernd W Scheithauer, Luis V Syro, Alejandro Velasquez, Eva Horvath, Kalman Kovacs Referencia : Endocr Pathol. Spring 2009;20(1):50-5. DOI (Digital Object Identifier) : 10.1007/s12022-009-9065-3 PMID : 19238590 En línea : https://link.springer.com/article/10.1007/s12022-009-9065-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4456 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000956 AC-2009-044 Archivo digital Producción Científica Artículos científicos Disponible Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma / Luis Vicente Syro MorenoPermalinkPermalinkRole of MGMT in tumor development, progression, diagnosis, treatment and prognosis / Luis Vicente Syro MorenoPermalinkSilent somatotroph adenoma of the pituitary in an adolescent / Luis Vicente Syro Moreno ; Verónica Abad LondoñoPermalinkMGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy / Luis Vicente Syro MorenoPermalinkTemozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings / Luis Vicente Syro MorenoPermalinkAntitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm / Luis Vicente Syro MorenoPermalinkPermalinkProlactin-producing pituitary adenoma associated with prolactin cell hyperplasia / Luis Vicente Syro MorenoPermalinkPermalink